Long-Standing Remission After Tildrakizumab Treatment in a Case of Refractory Type I Pityriasis Rubra Pilaris in a Breast Cancer Patient

Pityriasis rubra pilaris (PRP) is a rare chronic inflammatory skin disease characterised by follicular keratotic papules and perifollicular erythema coalescing into orange-red scaly plaques, and palmoplantar keratoderma. Characteristic islands of sparing are usually observed. A standardised therapeu...

Full description

Saved in:
Bibliographic Details
Published in:Clinical, cosmetic and investigational dermatology cosmetic and investigational dermatology, 2024-10, Vol.17, p.2297-2300
Main Authors: Di Lernia, Vito, Peccerillo, Francesca
Format: Article
Language:English
Subjects:
Breast cancer
Cancer patients
Care and treatment
Case Report
Development and progression
Health aspects
Interleukins
Patient compliance
pityriasis rubra pilaris
Refractories industry
Skin
Skin diseases
tildrakizumab
treatment
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pityriasis rubra pilaris (PRP) is a rare chronic inflammatory skin disease characterised by follicular keratotic papules and perifollicular erythema coalescing into orange-red scaly plaques, and palmoplantar keratoderma. Characteristic islands of sparing are usually observed. A standardised therapeutic approach is lacking owing to the infrequent occurrence of this disease. However, anti-interleukin (IL)-17 and anti-IL-23 therapies have recently emerged as effective therapies in patients affected by PRP, with improvements in severity scores, change in severity of erythema, scaling, and thickness of lesions. Here, we report a 43-year old, female breast cancer who developed severe refractory PRP, which greatly impacted her quality of life. The patient experienced a marked improvement after treatment with tildrakizumab. Treatment was stopped after one year, and the three-year follow-up did not show relapse. In conclusion, 52- week treatment with tildrakizumab, an IL-23 antagonist, proved to be a favourable treatment option for PRP, leading to good patient adherence, improvement in quality of life, and long-term follow-up without relapse.
ISSN:1178-7015
1178-7015
DOI:10.2147/CCID.S483166